Strategic priority for AMR

Transcription

1 Strategic priority for AMR Transforming our response to drug resistant infections Ghada Zoubiane PhD Science Lead Drug-Resistant Infections priority programme Joint Programming Initiative on AMR MB meeting 26 January 2018, Brussels

2 Where we work Vietnam Research Programme and Oxford University Clinical Research Unit Malawi-Liverpool- Wellcome Clinical Research Programme KEMRI-Wellcome Research Programme Wellcome-Mahidol University-Oxford Tropical Medicine Research Programme Africa Health Research Institute (AHRI)

3 Funding research globally to tackle AMR United States United Kingdom Denmark Ireland Belgium Hungary France Switzerland Spain China India Senegal Benin Colombia Ivory Coast Ghana Cameroon Kenya Wellcome has invested 287m in AMR activities since 2004, including: basic science ( 108), translation ( 122m) surveillance/epidemiology ( 34m) Peru Brazil South Africa Tanzania

4 Wellcome s priority programme

5 Wellcome s framework for supporting science Advancing ideas We support great ideas and inspired thinking Seizing opportunities We bring ideas together to make a difference Driving reform We change ways of working so more ideas can flourish

6 Wellcome s new strategic framework Seizing opportunities We bring ideas together to make a big difference We identify times when our concerted intervention can accelerate progress towards better health. We identify a critical need and set ambitious goals. We connect experts from different disciplines, build partnerships, and lead advocacy, policy development, communications and public engagement. We do this by providing focused, intensive support that creates a step change over five to ten years.

7 Wellcome s priority programme focused on AMR Will be Outcome / objective led Targeting research activities to deliver outcomes Commissioning work and inviting requests for proposals Influencing & advocating Building and catalysing partnerships Response-mode funding (Advancing Ideas) will still support AMR research as it always has Not a broad funding scheme for AMR Not pulling all AMR activities under one umbrella 7

8 Developing Wellcome Trust s strategic priority Seeking to transform the response to the threat of AMR by improving treatments, enabling policy and engaging communities Near-term goals Understanding emergence and transmission of AMR Increased pipeline of new therapeutics and diagnostics, and optimisation of existing Tx Accelerating development of new treatments for patients Coordinating activities toward common goals Long-term goals Paradigm shift in preventing and treating infections Coordinated international response to make healthcare systems resilient to threat of resistance Public mandate for change

9 Four pillars Wellcome is creating a global portfolio of open research and data to help guide national and global strategies for tackling drugresistant infections. Evidence for decision making New treatments Working with partners, Wellcome is funding the development of potential new antibiotics, diagnostics and preventative approaches. Drug-resistant infections Expertise Resources 175m over 5 years Wellcome is working with policy makers to support the development of a global framework to coordinate, monitor and evaluate progress. Effective global governance Faster clinical trials clinical With partners around the world, Wellcome is building global clinical trial networks to innovate and standardise protocols and make trials more efficient. 9

10 How we work and managing delivery Supporting investing in projects and activities Facilitating working with others to achieve shared goals Influencing persuade others to act Drug-Resistant Infection is a global health threat that undermines the progress made in the fight against infectious disease in the last century. 10

11 Evidence for decision making Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC) Global burden of antimicrobial resistance mapping project: Institute for Health Metrics and Evaluation and Big Data Institute at Oxford University Making industry antibiotic surveillance data open access Open Data Institute Joint WHO project for behaviour change 11

12 Launching SEDRIC Board convened January 12th. Public launch January 30 th as a side event at Prince Mahidol Awards Conference. 12

13 13

14 New treatments CARB-X Drug discovery pipeline 125m over 5 years with 34 projects so far in 7 countries (including India) Global Antibiotic Research and Development Partnership (GARDP) to work in partnership with the public and private sectors to develop and deliver new treatments for bacterial infections for which inadequate treatment exists Diagnostics Innovative Medicines Initiative to support the development of diagnostics Joint WHO project to develop Target Product Profiles for diagnostics 14

15 CARB-X Funding Rounds for 2018 Supporting innovation to fight drug-resistant bacteria Kevin Outterson 3/5/

16 What CARB-X funds Early development projects that address the serious bacterial threats antibiotics and therapeutics of all types rapid diagnostics preventives such as vaccines, microbiome Projects that target bacteria on the Antibiotic Resistance Threats List issued by the Centers for Disease Control and Prevention (CDC) in 2013 or on the Priority Bacterial Pathogens List published by the World Health Organization (WHO) in 2017

17 CARB-X funds projects in early development

18 CARB-X 2018 Funding Round 1 Scope of Round 1 New classes of direct-acting small molecule antibiotics and large molecule drugs that target priority Gram-negative bacteria Expressions of Interest (EOI) accepted on-line only EOI must be submitted March 22 through March 29, 2018, 5 pm EST Applying for Round 1? Mark your calendar March 22 29, 2018

19

20 CARB-X 2018 Funding Round 2 Scope of Round 2 Broad scope of therapeutics, vaccines, diagnostics and devices Expressions of Interest (EOI) accepted on-line only EOI must be submitted June 1 through June 8, 2018, 5 pm EST Applying for Round 2? Mark your calendar June 1-8, 2018

21

22 Applying for CARB-X funding, in summary CARB-X 2018 Funding Rounds will open for Expressions of Interest Round 1: March 22-29, 2018 Round 2: June 1-8, 2018 CARB-X welcomes applications from around the world Expressions of Interest applications must be submitted on-line at To qualify for funding and support, projects must be in scope and organizations must meet certain criteria The Powered by CARB-X portfolio is the world s largest and most scientifically diverse portfolio of early development antibacterial products to respond to the threat of the most serious drug-resistant bacteria More information:

23 Faster clinical trials Accelerated clinical development of new drugs and improved use of existing drugs Global clinical trial networks (GCTN) to support design, operation and interpretation Antibiotic Master Protocol Alliance (AMPA) to accelerate registration of new treatments 23

24 Effective global governance Helping governments (and others) develop and implement effective policies to limit the development and spread of drug-resistant infections Advocating for ambitious, sustained action e.g. access and stewardship, new incentive models for antibiotic development Global AMR Collaboration Hub (led by Germany) will help coordinate global R&D and serve to inform political decisions for investing Work with UN agencies including WHO to develop and support delivery of the Interagency Coordination Group 24

25 25

26 Team Strategic Advisory Group Technical Advisory Groups Alyson Fox (Sponsor) Tim Jinks Head of programme Ed Whiting Expert in Residence John Rex Expert in Residence Sharon Peacock Operations Manager Communications manager Admin support Science & Innovation Lead Ghada Zoubiane Policy & Advocacy Lead Jeremy Knox Francesca Chiara Janet Midega Joanna Wiecek Sian Williams Rebecca Sugden James Hynard In Global Policy Team Support from Legal, GM, I&A, Finance & Communincations 26

27 Follow us on #StopSuperbugs